Genetics of Drug Response in Diabetes

Ewan R. Pearson; Jose C. Florez

doi:10.1159/000362475

Genetics of Drug Response in Diabetes

Research output: Contribution to journal › Article › peer-review

Abstract

Patients with diabetes differ in how their diabetes responds to treatment. Some individuals can have a marked glycaemic response; others have a poor response. Some have adverse drug reactions (e.g. hypoglycaemia with sulphonylureas, or diarrhoea with metformin), others do not. Diabetes is one of the few disease areas (outside of cancer therapy) where pharmacogenetics is impacting on our understanding of drug mechanism, and on direct clinical care. In this review, we address the complexities of studying drug response in diabetes, and highlight key recent advances both within monogenic diabetes and common type 2 diabetes.

Original language	English
Pages (from-to)	158-172
Number of pages	15
Journal	Frontiers in Diabetes
Volume	23
DOIs	https://doi.org/10.1159/000362475
Publication status	Published - 2014

ASJC Scopus subject areas

Internal Medicine
Endocrinology, Diabetes and Metabolism
Endocrinology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1159/000362475

Cite this

@article{a347af6aeaf8441babae3036b78d5f54,

title = "Genetics of Drug Response in Diabetes",

abstract = "Patients with diabetes differ in how their diabetes responds to treatment. Some individuals can have a marked glycaemic response; others have a poor response. Some have adverse drug reactions (e.g. hypoglycaemia with sulphonylureas, or diarrhoea with metformin), others do not. Diabetes is one of the few disease areas (outside of cancer therapy) where pharmacogenetics is impacting on our understanding of drug mechanism, and on direct clinical care. In this review, we address the complexities of studying drug response in diabetes, and highlight key recent advances both within monogenic diabetes and common type 2 diabetes.",

author = "Pearson, {Ewan R.} and Florez, {Jose C.}",

year = "2014",

doi = "10.1159/000362475",

language = "English",

volume = "23",

pages = "158--172",

journal = "Frontiers in Diabetes",

issn = "0251-5342",

publisher = "S. Karger AG",

}

TY - JOUR

T1 - Genetics of Drug Response in Diabetes

AU - Pearson, Ewan R.

AU - Florez, Jose C.

PY - 2014

Y1 - 2014

N2 - Patients with diabetes differ in how their diabetes responds to treatment. Some individuals can have a marked glycaemic response; others have a poor response. Some have adverse drug reactions (e.g. hypoglycaemia with sulphonylureas, or diarrhoea with metformin), others do not. Diabetes is one of the few disease areas (outside of cancer therapy) where pharmacogenetics is impacting on our understanding of drug mechanism, and on direct clinical care. In this review, we address the complexities of studying drug response in diabetes, and highlight key recent advances both within monogenic diabetes and common type 2 diabetes.

AB - Patients with diabetes differ in how their diabetes responds to treatment. Some individuals can have a marked glycaemic response; others have a poor response. Some have adverse drug reactions (e.g. hypoglycaemia with sulphonylureas, or diarrhoea with metformin), others do not. Diabetes is one of the few disease areas (outside of cancer therapy) where pharmacogenetics is impacting on our understanding of drug mechanism, and on direct clinical care. In this review, we address the complexities of studying drug response in diabetes, and highlight key recent advances both within monogenic diabetes and common type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=84908605704&partnerID=8YFLogxK

U2 - 10.1159/000362475

DO - 10.1159/000362475

M3 - Article

AN - SCOPUS:84908605704

SN - 0251-5342

VL - 23

SP - 158

EP - 172

JO - Frontiers in Diabetes

JF - Frontiers in Diabetes

ER -

Genetics of Drug Response in Diabetes

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this